Search

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

EU projects

Creating a better world requires teamwork, partnerships, and collaboration. #bigdataforbloodcancer: Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.

Read more

Meeting program

October 11, 2023 at 3 pm CET The interaction of von Willebrand factor (VWF) with platelet glycoprotein Ib: pathological implications and clinical manifestations

15:00-15:10 Introduction                                                                                                Giancarlo Castaman, Paolo Gresele                           …

Read more

Accommodation

Welcome to the Hotel Accommodation page for the EHA2024 Hybrid Congress. Hotel Information and Official Housing Bureau

INTERPLAN AG is the official housing bureau for the EHA2024 Hybrid Congress.

Read more

Chairs and Members

Chair:
Francesco Buccisano, Department of Biomedicine and Prevention, Tor Vergata University of Rome, Italy (2021-2024)

Co-Chair:
Sylvie Freeman, Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK (2021-2024)

SWG Executive Board members and terms:

Torsten Haferlach, MLL Munich Leukemia Laboratory, Munich, Germany…

Read more

Press Release: Better funding for research into blood diseases will save more lives

“Haematology is probably the area of medicine that has progressed the most in recent years”, said Professor Robin Foà of “La Sapienza” University of Rome.

Read more